Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;204(1):31-44.
doi: 10.1111/bjh.19238. Epub 2023 Dec 6.

Primary central nervous system marginal zone lymphoma

Elena Flospergher  1 , Fabrizio Marino  1 , Teresa Calimeri  1 , Maria Giulia Cangi  2 , Andrés José María Ferreri  1   3 , Maurilio Ponzoni  2   3 , Lucia Bongiovanni  2   3
Affiliations
Review

Primary central nervous system marginal zone lymphoma

Elena Flospergher et al. Br J Haematol. 2024 Jan.

Abstract

Marginal zone lymphoma (MZL) is the most common indolent lymphoma primarily arising in the central nervous system (CNS). To date, 207 cases of primary CNS MZL (PCNSMZL) were published, mostly as single case reports or small case series. It most commonly presents as extra-axial dural-based masses, more frequently in middle-aged women, displaying an insidious onset, with a long history of symptoms preceding the diagnosis. PCNSMZL can be radiographically mistaken for meningioma. PCNSMZL consists of CD20+ , CD3- small B lymphocytes with varying degrees of plasmacytic differentiation and low proliferation index. Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality. Other recurrent genetic abnormalities involve TNFAIP3 and NOTCH2. Ethiopathogenesis was poorly investigated. Due to its rarity, standard of care remains to be defined; it exhibits an excellent prognosis after varied treatments, such as surgery, radiotherapy, chemotherapy or their combinations. Nevertheless, each treatment should be considered after an accurate analysis of overtreatment risk. Short follow-up is a major limitation in reported PCNSMZL cases, which restrains our knowledge on long-term results and iatrogenic sequels. This review was focussed on presentation, differential diagnoses, pathological findings, treatment options and clinical outcomes of PCNSMZL; recommendations for best clinical practice are provided.

Keywords: CNS lymphoma; marginal zone lymphoma; primary dural lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. https://doi.org/10.1016/j.annonc.2019.10.010
    1. Iwamoto FM, Abrey LE. Primary dural lymphomas: a review. Neurosurg Focus. 2006;21(5):E5.
    1. Karschnia P, Batchelor TT, Jordan JT, Shaw B, Winter SF, Barbiero FJ, et al. Primary dural lymphomas: clinical presentation, management, and outcome. Cancer. 2020;126(12):2811-2820.
    1. Desjardins C, Larrieu-Ciron D, Choquet S, Mokhtari K, Charlotte F, Nichelli L, et al. Chemotherapy is an efficient treatment in primary CNS MALT lymphoma. J Neurooncol. 2022;159(1):151-161. https://doi.org/10.1007/s11060-022-04052-1
    1. Iwamoto FM, DeAngelis LM, Abrey LE. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006;66(11):1763-1765.

MeSH terms

LinkOut - more resources